Product Overview
Generic name: Silymarin capsules
Chinese Pinyin: shuifeijisujiaonang
English name: Silymarin Capsules
Product name: Lijialong
Ingredients: Silymarin. Silymarin is a mixture of four isomers. One capsule contains 173.0-186.7 mg of dried milk thistle fruit extract (36-44:1), which is equivalent to 140 mg of silymarin based on silybin.
Properties: This product is a capsule, the content is yellow powder; the gas is slightly sweet and bitter.
Indications: Toxic liver damage: supportive treatment of chronic hepatitis and cirrhosis.
Specification: 140mg*10 tablets/box
Usage and dosage: The initial treatment dose for severe cases: 1 capsule once, three times a day; Maintenance dose: 1 capsule once, twice a day. Swallow with a moderate amount of liquid before meals. Or please follow the doctor's advice.
Adverse reactions: Some patients have mild diarrhea during use.
Taboo: People who are allergic to this product should not be used.
Note: Medication cannot replace the exclusion of factors that cause liver damage (such as alcohol). For cases of jaundice (light yellow or dark yellow skin, yellow eyes and sclera), consult a physician. This medicine is not suitable for the treatment of acute poisoning.
Drug interactions: The experiment has not been conducted and there is no reliable reference
Pharmacology and Toxicology: Ligaron is a liver disease treatment drug. It was first produced by Dr. Ma's large pharmaceutical factory in Germany, which specializes in the research and development of natural botanicals, and sold globally. Lijialong selects Silybum marianum seeds originating in the Mediterranean and is extracted through the exclusive patented technology MZ80 of Dr. Ma's Pharmaceutical Factory. 1. Pharmacology: It has been confirmed that in various pathological models of toxic liver damage, silymarin can neutralize muscarin, α-ammantin (a toxic substance found in Amanita phalloides), carbon tetrachloride, Poisoning caused by galactosamine and thioacetamide. The curative effect of silymarin is attributed to its several points of action and mechanism: due to its ability to trap free radicals, silymarin has anti-peroxidative activity. The pathophysiological process of lipid peroxidation (causing cell membrane damage) can be interrupted or prevented by silymarin. And in liver cells that have suffered damage, silymarin stimulates protein synthesis and normalizes phospholipid metabolism. In short, the greatest contribution of silymarin is to stabilize the liver cell membrane. It prevents or avoids the loss of lysed cellular components (such as transaminase). Silymarin can limit the penetration of certain hepatotoxic substances (such as α-ammantin) into the cell. The enhancement of protein synthesis ability is due to the fact that silymarin stimulates the activity of RNA polymerase I in the nucleus, thereby helping the synthesis of ribosomal RNA in liver cells, and at the same time leading to the synthesis of a large number of structural and functional proteins (enzymes). Therefore, silymarin can enhance the repair and regeneration capacity of damaged liver cells. Silymarin eliminates free radicals, reduces liver cell damage and liver tissue inflammation mediated by it, and inhibits the triggering of liver fibrosis; Lijialong is a treatment drug for liver disease, which is produced by Dr. Ma's large pharmaceutical factory in Germany, which specializes in natural botanical research The first production and sales worldwide. Lijialong selects Silybum marianum seeds originating in the Mediterranean and is extracted through the exclusive patented technology MZ80 of Dr. Ma's Pharmaceutical Factory. 1. Pharmacology: It has been confirmed that in various pathological models of toxic liver damage, silymarin can neutralize muscarin, α-ammantin (a toxic substance found in Amanita phalloides), carbon tetrachloride, Poisoning caused by galactosamine and thioacetamide. The curative effect of silymarin is attributed to its several points of action and mechanism: due to its ability to trap free radicals, silymarin has anti-peroxidative activity. The pathophysiological process of lipid peroxidation (causing cell membrane damage) can be interrupted or prevented by silymarin. And in liver cells that have suffered damage, silymarin stimulates protein synthesis and normalizes phospholipid metabolism. In short, the greatest contribution of silymarin is to stabilize the liver cell membrane. It prevents or avoids the loss of lysed cellular components (such as transaminase). Silymarin can limit the penetration of certain hepatotoxic substances (such as α-ammantin) into the cell. The enhancement of protein synthesis ability is due to the fact that silymarin stimulates the activity of RNA polymerase I in the nucleus, thereby helping the synthesis of ribosomal RNA in liver cells, and at the same time leading to the synthesis of a large number of structural and functional proteins (enzymes). Therefore, silymarin can enhance the repair and regeneration capacity of damaged liver cells. Silymarin eliminates free radicals, reduces liver cell damage and liver tissue inflammation mediated by it, and inhibits the triggering of liver fibrosis; in addition, it inhibits the mechanism of fibrosis by down-regulating type I collagen mRNA; and down-regulating tissue inhibitor of metalloproteinases -1mRNA, thereby inhibiting the synthesis of tissue inhibitor of metalloproteinase-1 and promoting the mechanism of collagen reduction. Therefore, silymarin has indirect and direct anti-fibrosis effects. 2. Toxicology: Silymarin is characterized by low toxicity and can be taken for a long time at a therapeutic dose. (1) Acute toxicity: A single-dose oral test in mice proves that silymarin is non-toxic, with LD50 greater than 2000mg/Kg. (2) Chronic toxicity: Rats and dogs were taken orally at the doses of 2500mg/kg and 1200mg/Kg for 12 consecutive months. The biochemical indexes and autopsy did not show any toxic effects. (3) Reproductive toxicity: The fertility studies conducted with rats and rabbits, and the prenatal, perinatal and postpartum toxicity studies did not find any side effects at all stages of reproduction (the maximum dose of the test: 2500mg/kg) . In particular, silymarin has not been shown to be a potential cause of teratogenesis. (4) Mutagenicity: In vitro and in vivo tests, silymarin showed a negative reaction
Pharmacokinetics: The main component of silymarin is silybin. Clinical studies have shown that after silymarin is absorbed through the digestive tract, it is mainly excreted with bile (more than 80% of the absorbed amount). It has been confirmed that glucuronide and sulfate are metabolites in bile. Silymarin is reabsorbed after being disconnected and enters the enterohepatic circulation. This process has been confirmed in animal experiments. Since silibinin may be eliminated mainly by bile (site of action: liver), the blood content is low and the renal elimination is low, the absorption half-life of this product is 2.2 hours, and the elimination half-life is 6.3 hours. When this product is taken in a therapeutic dose, the content of silybin in human bile after a single dose is the same as that of multiple doses. The results show that silibinin does not accumulate in the human body. After taking 140 mg of silymarin three times a day, bile clearance reached a stable state.
Medication for pregnant women and lactating women: There is no experience of using this product for pregnant women and lactating women. Therefore, pregnant and lactating women should use it with caution.
Children's medication: no reliable references
Medication for elderly patients: No such experiment and no reliable references
Overdose: If overdose is used, the original adverse reactions will expand. In this case, ask a doctor for symptomatic treatment.
Storage: Store in a cool, dry place.
Packing: Aluminum-plastic board, 10 tablets per board.
Validity period: 60 months
Executive standard: JX20030199
Approval number: Imported Drug Registration Certificate H20181067
Company name: MADAUS GMBH
